Biosergen AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '19 Dec 31, 2019
Net Income	-30.59	-19.2	-27.04	-34.05	-41.18	-
Other Operating Activities	-0.01	-	-	-	-0	-
Change in Accounts Receivable	1.37	2.91	-0.87	0.02	-	-
Change in Accounts Payable	7.07	7.07	-5.11	0.06	1.96	-
Change in Other Net Operating Assets	2.02	-0.96	0.42	4.52	-6.07	-
Operating Cash Flow	-20.15	-10.18	-32.6	-29.44	-45.3	-
Issuance of Common Stock	32.73	58.91	5.14	37.12	70.59	-
Financing Cash Flow	32.73	58.91	5.14	37.12	70.59	-
Net Cash Flow	12.32	48.73	-27.46	7.68	25.29	-
Cash Interest Paid	0.08	0.08	0.01	0.05	-	-
Levered Free Cash Flow	-15.27	-9.41	-23.83	-16.25	-	-
Unlevered Free Cash Flow	-15.27	-9.36	-23.82	-16.21	-	-
Change in Working Capital	10.46	9.02	-5.57	4.61	-4.12	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.